home / stock / lgnd / lgnd news


LGND News and Press, Ligand Pharmaceuticals Incorporated From 02/06/19

Stock Information

Company Name: Ligand Pharmaceuticals Incorporated
Stock Symbol: LGND
Market: NASDAQ
Website: ligand.com

Menu

LGND LGND Quote LGND Short LGND News LGND Articles LGND Message Board
Get LGND Alerts

News, Short Squeeze, Breakout and More Instantly...

LGND - Ligand Pharmaceuticals Q4 2018 Earnings Preview

Ligand Pharmaceuticals (NASDAQ: LGND ) is scheduled to announce Q4 earnings results on Thursday, February 7th, after market close. More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, , Healthcare stocks news, Read more ...

LGND - Ligand Announces Investment in Dianomi Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces closing an investment in Dianomi Therapeutics, Inc., a biopharmaceutical company focused on improving the delivery and efficacy of large and small molecules in the treatment of a variety of diseases and on therapies for inflammat...

LGND - Consolidated Research: 2019 Summary Expectations for Micron Technology, Quidel, Ligand Pharmaceuticals, Altra Industrial Motion, USG, and Equity Lifestyle Properties - Fundamental Analysis, Key Performance Indications

NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Micron Technology, Inc. (NASDAQ:MU), Quidel Corporation (NASDAQ:QDEL), Li...

LGND - Looking For Entry After Apricus And Seelos 'SEEL' The Deal

Seelos Therapeutics was a privately held biopharmaceutical company that recently finalized a reverse merger with Apricus Biosciences "APRI". This merger now allows Seelos to become a public traded company without going through the hassle of an IPO. The combined company is now trading under the...

LGND - Ligand Partner Seelos Therapeutics Becomes a Public Company

Proceeds from financing completed simultaneously with reverse merger to be used to fund pipeline which includes programs licensed from Ligand Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced that it has closed a reverse me...

LGND - Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders

NEW YORK, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) diso...

LGND - Goldman provides color on $168/share target on Ligand Pharma

Goldman Sachs analyst Dana Flanders provides the numbers behind his Street-low fair value target of $168 (46% upside) for Ligand Pharmaceuticals ( LGND -2.1% ) which makes money via licensing deals. More news on: Ligand Pharmaceuticals Incorporated, Healthcare stocks news, Stocks on the ...

Previous 10 Next 10